JP2017500849A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500849A5
JP2017500849A5 JP2016534133A JP2016534133A JP2017500849A5 JP 2017500849 A5 JP2017500849 A5 JP 2017500849A5 JP 2016534133 A JP2016534133 A JP 2016534133A JP 2016534133 A JP2016534133 A JP 2016534133A JP 2017500849 A5 JP2017500849 A5 JP 2017500849A5
Authority
JP
Japan
Prior art keywords
seq
peptide
transport
moiety
cargo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016534133A
Other languages
English (en)
Japanese (ja)
Other versions
JP6932506B2 (ja
JP2017500849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066619 external-priority patent/WO2015080943A1/en
Publication of JP2017500849A publication Critical patent/JP2017500849A/ja
Publication of JP2017500849A5 publication Critical patent/JP2017500849A5/ja
Application granted granted Critical
Publication of JP6932506B2 publication Critical patent/JP6932506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016534133A 2013-11-26 2014-11-20 細胞透過組成物およびそれを用いる方法 Active JP6932506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908963P 2013-11-26 2013-11-26
US61/908,963 2013-11-26
PCT/US2014/066619 WO2015080943A1 (en) 2013-11-26 2014-11-20 Novel cell-penetrating compositions and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020001263A Division JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Publications (3)

Publication Number Publication Date
JP2017500849A JP2017500849A (ja) 2017-01-12
JP2017500849A5 true JP2017500849A5 (cg-RX-API-DMAC7.html) 2017-12-28
JP6932506B2 JP6932506B2 (ja) 2021-09-08

Family

ID=53199565

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016534133A Active JP6932506B2 (ja) 2013-11-26 2014-11-20 細胞透過組成物およびそれを用いる方法
JP2020001263A Pending JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020001263A Pending JP2020072716A (ja) 2013-11-26 2020-01-08 細胞透過組成物およびそれを用いる方法

Country Status (5)

Country Link
US (2) US9908915B2 (cg-RX-API-DMAC7.html)
EP (1) EP3074049B1 (cg-RX-API-DMAC7.html)
JP (2) JP6932506B2 (cg-RX-API-DMAC7.html)
ES (1) ES2806027T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015080943A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2993671T3 (en) 2013-03-15 2025-01-03 Univ Texas Peptide fttftvt for use in treating fibrosis
EP3849580A4 (en) 2018-09-10 2022-06-15 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
US20230065816A1 (en) * 2020-02-07 2023-03-02 The Reasearch Foundation For Suny Methods for preventing and reversing opioid analgesic tolerance in subjects with chronic pain

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002876A (en) 1986-09-22 1991-03-26 Phillips Petroleum Company Yeast production of human tumor necrosis factor
US5004688A (en) 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
DK0632720T3 (da) 1992-03-25 1999-07-26 Depomed Inc Hydroxyethylcellulosebaserede depotpræparat-doseringsformer
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
MXPA02004413A (es) 1999-11-02 2002-09-02 Depomed Inc Induccion farmacologica del modo de alimentacion, para la administracion aumentada de drogas al estomago.
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20020077283A1 (en) 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
EP1438027A1 (en) 2001-10-25 2004-07-21 DepoMed, Inc. Methods of treatment using a gastric retained losartan dosage
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003064614A2 (en) 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US7473531B1 (en) * 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7250398B2 (en) * 2003-09-12 2007-07-31 Novozymes A/S Synthetic antimicrobial polypeptides
CN101511181B (zh) * 2006-07-11 2013-08-21 新泽西医科和牙科大学 蛋白、编码该蛋白的核酸和相关的应用方法
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US8309034B2 (en) * 2007-06-09 2012-11-13 Honeywell International Inc. Compositions, methods and devices for control and clean-up of hazardous spills
CA2709937C (en) * 2007-12-21 2016-03-22 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
CN102016058A (zh) * 2008-02-21 2011-04-13 伯纳姆医学研究所 与具有c端元件的肽和蛋白相关的方法和组合物
WO2010030813A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Methods for inhibiting ocular angiogenesis
US20150141340A1 (en) 2012-06-04 2015-05-21 Yale University Method of treating and preventing ocular angiogenesis
ES2743622T3 (es) * 2013-11-26 2020-02-20 E & B Tech Llc Tratamiento de la enfermedad autoinmune y/o inflamatoria usando moduladores de la caveolina novedosos

Similar Documents

Publication Publication Date Title
ES2484796T3 (es) Compuestos de GLP-1 extendidos
ES2350051T3 (es) Compuestos de glp-1 acilados.
JP2014520120A5 (cg-RX-API-DMAC7.html)
US20110256130A1 (en) Methods of treating inflammatory disorders
JP2009521908A5 (cg-RX-API-DMAC7.html)
JP2016512213A5 (cg-RX-API-DMAC7.html)
JP2011526886A5 (cg-RX-API-DMAC7.html)
WO2020156513A1 (zh) 双配体药物偶联体及其用途
JP2012505902A5 (cg-RX-API-DMAC7.html)
JP2010508305A5 (cg-RX-API-DMAC7.html)
JP2012529296A5 (cg-RX-API-DMAC7.html)
JP2014525901A5 (cg-RX-API-DMAC7.html)
JP2015522264A5 (cg-RX-API-DMAC7.html)
IL240686A (en) Preparations containing cyclic peptides containing adjacent arginine residues
JP2011508785A5 (cg-RX-API-DMAC7.html)
JP6158097B2 (ja) 炎症を抑制するためのペプチド
US20210395303A1 (en) Mini-nucleosome core proteins and use in nucleic acid delivery
JP2017500849A5 (cg-RX-API-DMAC7.html)
EP2766384B1 (en) Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
JP2022502347A (ja) 細胞透過性ペプチド
JP2019507182A (ja) 炎症を処置するための化合物および方法
JP2015513314A5 (cg-RX-API-DMAC7.html)
JP2019038772A5 (cg-RX-API-DMAC7.html)
US10632187B2 (en) Hemagglutinin-binding peptide
JP2006523608A5 (cg-RX-API-DMAC7.html)